High dose daily amifostine and hypofractionated intensively accelerated radiotherapy for locally advanced breast cancer. A phase I/II study and report on early and late sequel

Anticancer Research

Volumn 21, Issue 4 B, 2001, Pages 2973-2978

  Koukourakis, M I ^a   Yannakakis, D ^a  

^a Tumour and Angiogenesis Res Group   (Greece)

Author keywords

Acceleration; Amifostine; Breast cancer; Hypofractionation; Radiotherapy

Indexed keywords

AMIFOSTINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL PROTECTION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG MEGADOSE; DRUG TOLERABILITY; HUMAN; HYPOTENSION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIOSENSITIVITY; REOXYGENATION; SKIN TOXICITY; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; AMIFOSTINE; ARM; BRACHIAL PLEXUS; BREAST; BREAST NEOPLASMS; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; EDEMA; FEASIBILITY STUDIES; FEMALE; FIBROSIS; HUMANS; HYPOTENSION; MIDDLE AGED; PERIPHERAL NERVOUS SYSTEM DISEASES; PULMONARY FIBROSIS; RADIATION INJURIES; RADIATION PNEUMONITIS; RADIATION-PROTECTIVE AGENTS; RADIODERMATITIS; RADIOTHERAPY, HIGH-ENERGY; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VOMITING;

EID: 0035170486     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Biological basis for altered fractionation schemes
2. Intervals between multiple fractions per day. Differences between early and late reactions
3. Alpha/beta and the importance of the size of dose per fraction for late complications in the supraglottic larynx
4. Hypofractionation: Lessons from complications
5. Clinical radiobiology of malignant melanoma
6. Inherent cellular radiosensitivity as a basic concept for human tumor radiotherapy
7. Hypoxic cells and their importance in radiotherapy
8. The inactivation of Chinese hamster cells by x-rays: The effect of chemical modifiers on single and double -events
9. Reduced oxygen enhancement ratio at low dose of ionizing radiation
10. The phenomenon of reoxygenation and its implications for fractionated radiotherapy
11. Stage III carcinoma of the uterine cervix: Retrospective analysis of prognostic factors concerning patient characteristics and treatment parameters
12. T1/T2 glottic cancer managed by external beam radiotherapy: The influence of pretreatment hemoglobin on local control
13. What have we learnt from hyperbanc oxygen?
14. Angiogenesis vs. response after combined chemo-radiatherapy of squamous cell head and neck cancer
15. 'Invading edge vs. inner' (edvin) patterns of vascularisation: An interplay between angiogenic and vascular survival factors defines clinical behavior of non-small cell lung cancer
16. Tumor hypoxia and the positron data paradox
17. The molecular basis of hypoxia response pathway: Tumor hypoxia as a therapy target
18. The hazards of accelerated tumor clonogene repopulation during radiotherapy
19. Randomized multicenter trials of CHART vs conventional radiotherapy in head-neck and non-small cell lung cancer. An interim report
20. The impact of overall treatment time on the results of radiatherapy for non-small cell lung cancer
21. Dose fractionation and regeneration in radiatherapy for cancer of the oral cavity and oropharynx: Tumor dose-response and repopulation
22. Dose fractionation and tumour repopulation in radiotherapy for bladdercancer
23. Overall treatment time in advanced cervical carcinomas: A critical parameter in treatment outcome
24. Hypofractianated radiatherapy for invasive bladder cancer
25. Carcinoma of the larynx treated with hypofractianated radiation and hyperbaric oxygen: Long-term tumor control and complications
26. Hypofractionated irradiation for inoperable non-small cell lung cancer
27. Impact of radiation therapy fraction size on local cantrol of early glattic carcinoma
28. Hypofractionated radiatherapy with 5-fluorouracil radiosensitization for locally "far advanced" breast cancer
29. Hypofractionated radiatherapy with concurrent 5-fluorouracil radiosensitisation for recurrent or locally advanced colorectal cancer. A phase II study
30. High dose hypofractionated radiotherapy with concommitant 5-Fluorouracil in the treatment of advanced sarcomas of the bone. A Pilot study
31. Thiol and disulfide metabolites of the radiation protector and potential chemopreventive agent WR2721 are linked to both its anticytotoxic and antimutagenic mechanisms of action
32. A randomized phase III trial of radiation + Amifostine in patients with head and neck cancer
33. Expanded application for Ethyol (Amifostine): The role of Ethyol (Amifostine) as a radioprotector in lung cancer
34. The use of Ethyol in chemotherapy and radiation therapy
35. LENT SOMA tables
36. LQ-based model for biological radiotherapy planning
37. Dose fractionation and regeneration in radiotherapyforcancer of the oral cavityand oropharynx. Part 2. Normal tissue responses: Acute and late effects
38. Hypoxic cervical carcinomas with low apoptotic index are highly aggressive
39. Is α/β for prostate tumors really low?